– CE-Ventures co-led a USD 10 million funding round for CrossBridge Bio, a Houston-based biotech firm developing dual-payload ADCs for targeted cancer therapies. 

– The investment will help advance CrossBridge Bio’s lead candidate, CBB-120, for solid tumors, while also expanding its dual-payload ADC pipeline and proprietary linker technology. 

– Other investors in the round include TMC Venture Fund, Portal Innovations, Alexandria Ventures, and several pre-seed investors, supporting CrossBridge Bio’s efforts to revolutionize cancer therapy.

CE-Ventures, the corporate venture capital arm of UAE-based Crescent Enterprises, has co-led a $10 million financing round for CrossBridge Bio. The Houston-based biotech firm is specializing in dual-payload antibody-drug conjugates (ADCs) for targeted cancer therapies.

Funding to Support Cancer Therapy Innovation

So, the funding round, co-led with TMC Venture Fund, will support CrossBridge Bio’s efforts to advance its lead candidate, CBB-120, for the treatment of solid tumors. It will also expand the company’s dual-payload ADC pipeline. Additionally, the funds will accelerate the development of CrossBridge Bio’s proprietary linker technology. That technology is a key component for improving the safety and effectiveness of its therapies.

Crescent Enterprises’ Commitment to Life Sciences

“Crescent Enterprises is dedicated to further expanding our life science portfolio with cutting-edge biotech companies,” said Tushar Singhvi, Deputy CEO and Head of Investments at Crescent Enterprises. “CrossBridge Bio exemplifies the innovation in therapeutic drug development.”

Additionally,Damir Illich, PhD, Manager Life Sciences at CE-Ventures added: “CrossBridge Bio is a new leader in the dual-payload ADC drug discovery. We are proud to support their efforts to advance the lead candidate CBB-120 through preclinical studies…”

“We are proud to have the support of such experienced investors who share our vision of transforming cancer therapy,” said Michael Torres, PhD, CEO of CrossBridge Bio.

“Our dual-payload ADC technology is also designed to maximize therapeutic effectiveness by delivering targeted therapies directly into cancer cells. It will minimize potential off-target effects.

CrossBridge Bio Plans to Advance CBB-120

Futhermore, Michael Torres, PhD, CEO of CrossBridge Bio, expressed, “We’re excited to have the support of investors who share our vision of transforming cancer therapy. Our dual-payload ADC technology maximizes therapeutic effectiveness. With this funding, we will move CBB-120 into preclinical toxicology studies.”

Read More: Dammam Valley launches a BioTech Startups Programme